Core dashboard

  • Organic Revenue Growth - capture the reported value, direction, source, management explanation, and thesis implication.
  • Procedure Or Prescription Volume - capture the reported value, direction, source, management explanation, and thesis implication.
  • Gross Margin - capture the reported value, direction, source, management explanation, and thesis implication.
  • Research And Development Spending - capture the reported value, direction, source, management explanation, and thesis implication.
  • Operating Margin - capture the reported value, direction, source, management explanation, and thesis implication.
  • Free Cash Flow - capture the reported value, direction, source, management explanation, and thesis implication.
  • Pipeline Milestones - capture the reported value, direction, source, management explanation, and thesis implication.
  • Installed Base - capture the reported value, direction, source, management explanation, and thesis implication.
  • Recurring Service Or Consumables Mix - capture the reported value, direction, source, management explanation, and thesis implication.
  • Reimbursement Trends - capture the reported value, direction, source, management explanation, and thesis implication.

Before earnings or a filing

Review the prior quarter's expectations, unresolved questions, and thesis breakers. Record what you expect to learn from the next filing without predicting a stock-price reaction. This prevents hindsight from rewriting the original thesis.

After the filing

Start with reported statements, notes, and reconciliations. Update the dashboard, then read management discussion. Separate changes caused by volume, price, mix, currency, acquisitions, accounting, and one-time items. Reconcile cash flow and share count, not just earnings per share.

Competitive check

Compare relevant evidence with Johnson & Johnson, Lilly (Eli), Merck & Co., Pfizer, Viatris, Zoetis. Determine whether a trend is company-specific or industry-wide. Use comparable definitions and periods.

Macro check

Review health-care utilization, employment and insurance coverage, government reimbursement policy, interest rates for provider capital budgets, demographics, biopharma research spending. Only elevate a macro variable when there is a defensible channel into Bristol Myers Squibb's demand, pricing, costs, financing, or asset values.

Change log

Maintain a dated log with four labels: fact, interpretation, scenario, and unknown. Link every time-sensitive factual change to a primary source. If a prior assumption is wrong, preserve the old entry and explain the revision rather than silently rewriting history.

References

The evergreen analysis above is anchored to verified index metadata and a filing-first research workflow. Time-sensitive financial figures should be refreshed from the latest primary filings before publication or material updates.

  • S&P Dow Jones Indices - S&P 500: https://www.spglobal.com/spdji/en/indices/equity/sp-500/
  • SEC EDGAR company filings for Bristol Myers Squibb: https://www.sec.gov/edgar/browse/?CIK=14272&owner=exclude&action=getcompany
  • SEC submissions JSON for CIK 14272: https://data.sec.gov/submissions/CIK0000014272.json
  • Current constituent registry snapshot used for this build: https://github.com/chinobing/historical_sp500_constituents/blob/main/sp500_constituents.csv

Source-review rule: Before publishing a statement about current revenue, margins, management, products, segment mix, guidance, market share, or capital allocation, verify it against the latest 10-K, 10-Q, 8-K, proxy statement, earnings release, or official investor-relations material. This page deliberately avoids inventing those facts when they were not present in the constituent registry used to generate the batch.